Cardiovascular Drugs in Veterinary Medicine

Overview

This document provides comprehensive notes on cardiovascular drugs, detailing normal cardiac function, the mechanisms of action for various drugs, and the classification of these drugs used in veterinary medicine. The information is sourced from Bill’s Clinical Pharmacology and Therapeutics for Veterinary Technicians, (5th ed.) by Anderson, M. (2024).

Normal Cardiac Function

Understanding the heart's structure and function is crucial for recognizing how blood flows through the heart in approximately 60 seconds, involving multiple key components:

Atria: Left Atria receives oxygenated blood from the lungs via the pulmonary veins, while the Right Atria collects deoxygenated blood from the body through the superior and inferior vena cavae.
Ventricles: The Left Ventricle pumps oxygenated blood to the systemic circulation through the aorta, while the Right Ventricle sends deoxygenated blood to the pulmonary arteries leading to the lungs for reoxygenation.
Valves: The heart contains valves such as the tricuspid valve (between the right atrium and right ventricle) and the mitral valve (between the left atrium and left ventricle), which ensure unidirectional blood flow and prevent backflow during contractions.

Preload and Afterload

Preload

Refers to the volume/force of blood received by the ventricles from the atria prior to contraction.
Decrease in Preload: Can occur due to factors like dehydration, severe blood loss, or the effects of certain pharmacological agents that promote venodilation.
Increase in Preload: Often results from the administration of intravenous fluids, the presence of edema, or clinical conditions such as congestive heart failure leading to pulmonary edema.

Afterload

Represents the physical resistance the ventricles face when ejecting blood into the arteries during systole.
Decrease in Afterload: This can be due to conditions such as mitral valve insufficiency, which decreases systemic pressure, or the use of afterload-reducing medications.
Increase in Afterload: Commonly associated with structural heart conditions such as aortic stenosis or systemic hypertension, which increases the workload and oxygen demand on the heart muscle.

Electrical Conduction of the Heart

The heart’s electrical activity is crucial for coordinated contractions and is regulated by:

S-A Node (Sinoatrial Node): The primary pacemaker of the heart, responsible for initiating electrical impulses that lead to heartbeats.
A-V Node (Atrioventricular Node): Acts as a gatekeeper, momentarily delaying the electrical signal before it moves to the ventricles, allowing for proper filling of the ventricles.
Bundle of His and Purkinje Fibers: This system distributes electrical impulses throughout the ventricles, facilitating synchronized contraction and effective blood ejection.

Autonomic Control of Heart Function

The autonomic nervous system regulates heart function through two branches:

Sympathetic System: Increases heart rate and contractility through the release of norepinephrine, optimizing the body's response during stress or exercise.
Parasympathetic System: Primarily mediated by the vagus nerve, this system decreases the heart rate through acetylcholine release, promoting rest and recovery states.

Abnormalities of the Cardiovascular System

Potential issues in the cardiovascular system include:

Valvular Disease: Characterized by improper opening or closing of the heart valves, which can lead to murmur and heart failure.
Myocardial Disease: Results in inadequate pumping capacity or relaxation of the heart muscle, often seen in cardiomyopathies.
Arrhythmia: Abnormal heart rhythms ranging from bradycardia (slow heart rate) to tachycardia (fast heart rate) and arrhythmic patterns that can be life-threatening.
Vascular Disease: Conditions like atherosclerosis or thrombosis that obstruct normal blood flow, leading to ischemic damage.
Cardiac Shunts: Abnormal connections between heart chambers (arterial or venous), often resulting in mixed oxygenated and deoxygenated blood.
Blood Volume Discrepancies: Situations where blood volume is inadequate or excessive for the capacity of vessels, leading to shock or hypertension, respectively.
Parasitism: Conditions like heartworm disease (Dirofilaria immitis) seriously affect cardiovascular function and can lead to severe heart failure if untreated.

Renin-Angiotensin-Aldosterone System (RAAS)

A crucial regulatory mechanism that influences blood pressure and fluid balance through its components:

Renin: An enzyme released from the kidneys in response to low blood pressure, leading to the conversion of angiotensinogen to angiotensin I.
Angiotensin II: A potent vasoconstrictor that increases blood pressure and stimulates the release of aldosterone, prompting sodium reabsorption in the kidneys, thus influencing preload and afterload dynamics.

Antiarrhythmic Drugs

These drugs are classified based on their mechanisms of action:

Class I: Sodium Channel Blockers

Mechanism: Decrease the influx of sodium ions during depolarization, stabilizing cell membranes.
Drug Examples: Quinidine, procainamide, lidocaine, mexiletine.
Indications: Primarily used for controlling ventricular arrhythmias and atrial fibrillation.
Side Effects: Variable and include potential for gastrointestinal upset, sedation, and seizures.

Class II: Beta Blockers

Mechanism: Block β-adrenergic receptors, reducing the effects of adrenaline on the heart, resulting in lowered heart rate and contractility.
Drug Examples: Propranolol, atenolol, metoprolol.
Indications: Treat arrhythmias, hypertension, and heart failure.
Side Effects: Can include bradycardia, lethargy, and hypotension, necessitating careful monitoring.

Class III: Potassium Channel Blockers

Mechanism: Slow the opening of potassium channels, prolonging action potentials and refractory periods.
Drug Examples: Sotalol, amiodarone.
Indications: Effective for serious ventricular arrhythmias.
Side Effects: Risks include development of new arrhythmias and may lead to bronchoconstriction in susceptible animals.

Class IV: Calcium Channel Blockers

Mechanism: Inhibit calcium influx in cardiac and vascular smooth muscle, decreasing contractility.
Drug Examples: Verapamil, diltiazem.
Indications: Used for conditions like supraventricular tachycardia and atrial fibrillation.
Side Effects: Reductions in contractility may lead to decreased cardiac output, requiring close stabilization.

Heart Failure Treatment

Key Approaches

Fluid Management: Administering diuretics such as furosemide to alleviate pulmonary edema and monitor fluid retention efficiently.
Shutting Down RAAS: Employing ACE inhibitors and mixed vasodilators to prevent further fluid retention and cardiac overload.
Improving Cardiac Function: Utilization of inodilators like pimobendan which enhance contractility while also providing vasodilation.

Diuretics

Loop Diuretics: e.g., Furosemide, specifically indicated for managing pulmonary edema and excess fluid in tissues.
Potassium-Sparing Diuretics: e.g., Spironolactone, critical for maintaining potassium homeostasis while managing heart failure symptoms.

Case Studies: Veterinary Patients

Several case studies illustrate practical applications of the aforementioned treatments, reflecting various presentations of heart disease in veterinary patients, including:

Brutus, a Doberman exhibiting signs of severe arrhythmias, was successfully treated with intravenous antiarrhythmics and rate control strategies.
Godzilla, a bearded dragon demonstrating cardiovascular disease, underwent echocardiography which revealed significant ventricular dilatation, leading to tailored management involving specific cardiac therapies.

Resources

Anderson, M. (2024). Bill’s Clinical Pharmacology and Therapeutics for Veterinary Technicians, (5th ed.). Elsevier.
Budde, J.A., McCluskey, D.M. (2023). Plumb’s Veterinary Drug Handbook, (10th ed.). Wiley-Blackwell.
Martini-Johnson, L.A. (2021). Applied Pharmacology for Veterinary Technicians, (6th ed.). Elsevier.
Ozawa, S.M. et al. (2024). Cardiovascular disease in central bearded dragons. American Journal of Veterinary Research.
Peterson, M.E. et al. (2013). Small Animal Toxicology, (3rd ed.). Elsevier.